Cargando…

P900: SALVAGE AUTOLOGOUS STEM CELL TRANSPLANT IN RELAPSED MULTIPLE MYELOMA: A SINGLE CENTRE EXPERIENCE

Detalles Bibliográficos
Autores principales:	Duarte, S., Roque, A., Mota, D., Carda, J., Geraldes, C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430752/ http://dx.doi.org/10.1097/01.HS9.0000846472.10254.dd

Ejemplares similares

P1303: DARATUMUMAB-BASED MAINTENANCE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA AFTER SALVAGE AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Pasvolsky, Oren, et al.
Publicado: (2023)

P1358: WILL COVID-19 PANDEMIC CHANGE MOBILIZATION STRATEGY OF HEMATOPOIETIC STEM CELLS IN MULTIPLE MYELOMA PATIENTS FOR THE BETTER?
por: Marques, B., et al.
Publicado: (2022)

P1671: CARFILZOMIB-DEXAMETHASONE MAINTENANCE HAMPERS RECOVERY AFTER SALVAGE AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA
por: Nielsen, Lene Kongsgaard, et al.
Publicado: (2023)

Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma
por: Yarlagadda, Lakshmi, et al.
Publicado: (2021)

Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma
por: Baertsch, Marc-Andrea, et al.
Publicado: (2021)

Outcomes of Salvage Autologous Versus Allogeneic Hematopoietic Cell Transplantation for Relapsed Multiple Myeloma After Initial Autologous Hematopoietic Cell Transplantation
por: Wirk, Baldeep, et al.
Publicado: (2013)

Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma
por: Hus, Marek, et al.
Publicado: (2011)

The Impact of Re-induction Prior to Salvage Autologous Stem Cell Transplantation in Multiple Myeloma
por: Miller, Kevin C., et al.
Publicado: (2019)

Non-interventional Study Evaluating the Mobilization of Stem Cells by Plerixafor Before Salvage Autologous Stem Cell Transplant in Relapsed Multiple Myeloma (IFM-2015-03)
por: van de Wyngaert, Zoe, et al.
Publicado: (2023)

Patient-Reported Outcome Results From the Open-Label, Randomized Phase III Myeloma X Trial Evaluating Salvage Autologous Stem-Cell Transplantation in Relapsed Multiple Myeloma
por: Ahmedzai, Sam H., et al.
Publicado: (2019)

Pulmonary Lymphangitic Spread of Multiple Myeloma as Early Relapse after Autologous Stem Cell Transplantation
por: Thapa, Bicky, et al.
Publicado: (2021)

Staging System to Predict the Risk of Relapse in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
por: Goswami, Chitrita, et al.
Publicado: (2019)

Feasibility and efficacy of salvage allogeneic stem cell transplantation in AML patients relapsing after autologous stem cell transplantation
por: Shumilov, Evgenii, et al.
Publicado: (2021)

P1376: LENALIDOMIDE–BASED MAINTENANCE AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT FOR PATIENTS WITH HIGH RISK MULTIPLE MYELOMA
por: Pasvolsky, O., et al.
Publicado: (2022)

P1279: OUTCOMES OF AUTOLOGOUS STEM CELL TRANSPLANT IN PATIENTS WITH MULTIPLE MYELOMA WITH TWO OR MORE HIGH-RISK CYTOGENETIC ABNORMALITIES
por: Pasvolsky, Oren, et al.
Publicado: (2023)

The impact of COVID-19 on autologous stem cell transplantation in multiple myeloma: A single-centre, qualitative evaluation study
por: Camilleri, Marquita, et al.
Publicado: (2022)

Prognostic nomogram for multiple myeloma early relapse after autologous stem cell transplant in the novel agent era
por: Zhou, Huixing, et al.
Publicado: (2023)

P43 CIRCULATING CLONAL PLASMA CELLS AT START OF SALVAGE REGIMEN PROVIDE POWERFUL PROGNOSTICATION BIOMARKER IN MULTIPLE MYELOMA PATIENTS AT FIRST RELAPSE
por: Romano, A., et al.
Publicado: (2023)

Current status of autologous stem cell transplantation for multiple myeloma
por: Al Hamed, Rama, et al.
Publicado: (2019)

P1299: OUTCOMES OF YOUNG ADULTS (AGED ≤40 YEARS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UPFRONT AUTOLOGOUS STEM CELL TRANSPLANT
por: Pasvolsky, Oren, et al.
Publicado: (2023)

Immunogenicity of Covid-19 Vaccine Among Multiple Myeloma Patients Post Autologous Stem Cell Transplant
por: Thalambedu, Nishanth, et al.
Publicado: (2023)

Comparison of single and double autologous stem cell transplantation in multiple myeloma patients
por: Malkan, Umit Yavuz, et al.
Publicado: (2021)

P17 CLONAL PLASMA-CELLS IN STEM CELL APHERESIS AS A PREDICTOR OF PROGRESSION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS ELEGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION
por: Pilerci, S., et al.
Publicado: (2023)

P1443: AUTOLOGOUS NK CELLS AS CONSOLIDATION AFTER FRONT-LINE STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA: A LONG-TERM FOLLOW-UP
por: Lund, J., et al.
Publicado: (2022)

Successful Treatment of Gastric Relapse in Multiple Myeloma with Bortezomib after Autologous Hematopoietic Stem Cell Transplantation (autoHSCT)
por: Sivgin, Serdar, et al.
Publicado: (2013)

Isolated central nervous system relapse of multiple myeloma post autologous stem cell transplant- A rare presentation
por: Mittal, Abhenil, et al.
Publicado: (2020)

Allogeneic or autologous stem cell transplantation following salvage chemotherapy for adults with refractory or relapsed acute lymphoblastic leukemia
por: Martino, R, et al.
Publicado: (1998)

P50 OVERALL SURVIVAL ADVANTAGE OF MONOCLONAL ANTIBODIES BASED-TREATMENTS IN MULTIPLE MYELOMA PATIENTS RELAPSED AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
por: Nozzoli, C., et al.
Publicado: (2023)

Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma without Cryopreservation
por: Al-Anazi, Khalid Ahmed
Publicado: (2012)

Update on the Role of Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
por: Tosi, P., et al.
Publicado: (2012)

Complete response after autologous stem cell transplant in multiple myeloma
por: Kumar, Lalit, et al.
Publicado: (2014)

Post-Autologous (ASCT) Stem Cell Transplant Therapy in Multiple Myeloma
por: Al-Mansour, Zeina, et al.
Publicado: (2014)

Characteristics of exceptional responders to autologous stem cell transplantation in multiple myeloma
por: Paquin, Ashley, et al.
Publicado: (2020)

Interrupted Identities: Autologous Stem Cell Transplant in Patients With Multiple Myeloma
por: Halpin, Sean N, et al.
Publicado: (2021)

Outcomes of autologous stem cell transplantation for multiple myeloma in Saudi Arabia
por: Abdrabou, Ahmed Kotb, et al.
Publicado: (2021)

Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma
por: Srour, Samer A., et al.
Publicado: (2021)

P923: TANDEM AUTOLOGOUS STEM CELL TRANSPLANTATIONS STILL BENEFIT FOR MYELOMA PATIENTS: A POOLING META-ANALYSIS
por: Lee, C.-H., et al.
Publicado: (2022)

Impact of tandem autologous stem cell transplantation and response to transplant in the outcome of multiple myeloma
por: Bergantim, Rui, et al.
Publicado: (2012)

Sequential, Autologous Hematopoietic Stem Cell Transplant Followed by Renal Transplant in Multiple Myeloma
por: Bhowmik, D., et al.
Publicado: (2017)

Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes
por: Hari, P, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ja7ednr4h0gq30m8d37ruttf4r